Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

v3.21.2
Note 14 - Segments (Tables)
9 Months Ended
Sep. 30, 2021
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]

Three Months Ended September 30, 2021

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

License revenue

  $ 9,116     $     $     $ 9,116  

Grant and other revenue

    87,266                   87,266  

Total revenue

    96,382                   96,382  

Research and development expenses

    906,677       142,109             1,048,786  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          744       1,450,565       1,451,309  

Depreciation and amortization (2)

    6,040             12,026       18,066  

Loss from operations (3)

    (816,335

)

    (142,853

)

    (1,462,591

)

    (2,421,779

)

Other expense (4)

                (14

)

    (14

)

Income tax expense

    (5,763

)

    (824

)

    (9,457

)

    (16,043

)

Net loss

    (822,098

)

    (143,677

)

    (1,472,062

)

    (2,437,836

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 185,205     $     $ 8,557,398     $ 8,742,603  

International

    216,353             590       216,943  

Capital expenditures

                18,042       18,042  

Three Months Ended September 30, 2020

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Royalty revenue

  $ 2,047     $     $     $ 2,047  

License revenue

    4,726                   4,726  

Grant and other revenue

    106,729       154,887             261,616  

Total revenue

    113,502       154,887             268,389  

Cost of revenue

    82                   82  

Research and development expenses

    1,251,383       126,615             1,377,998  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

                1,773,532       1,773,532  

Depreciation and amortization (2)

    4,027             11,375       15,402  

(Loss) income from operations (3)

    (1,268,605

)

    28,272       (1,784,907

)

    (2,898,625

)

Other expense (4)

                (713

)

    (713

)

Net (loss) income

    (1,141,990

)

    28,272       (1,785,620

)

    (2,899,338

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 1,000     $ 38,320     $ 5,839,733     $ 5,879,053  

International

    116,782                   116,782  

Capital expenditures

    120,810                   120,810  

Nine Months Ended September 30, 2021

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

License revenue

  $ 44,665     $     $     $ 44,665  

Grant and other revenue

    436,500                   436,500  

Total revenue

    481,165                   481,165  

Research and development expenses

    3,359,190       410,406             3,769,596  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          3,623       5,073,435       5,077,058  

Depreciation and amortization (2)

    18,121             37,551       55,672  

Loss from operations (3)

    (2,896,146

)

    (414,029

)

    (5,110,986

)

    (8,421,161

)

Other income (4)

                358,436       358,436  

Income tax expense

    (5,763

)

    (824

)

    (9,457

)

    (16,043

)

Net loss

    (2,901,909

)

    (414,853

)

    (4,762,007

)

    (8,078,768

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 185,205     $     $ 8,557,398     $ 8,742,603  

International

    216,353             590       216,943  

Capital expenditures

                20,749       20,749  

Nine Months Ended September 30, 2020

 

Diagnostics

   

Therapeutics

   

Corporate

   

Total

 

Royalty revenue

  $ 26,188     $     $     $ 26,188  

License revenue

    4,726                   4,726  

Grant and other revenue

    381,103       283,745             664,848  

Total revenue

    412,017       283,745             695,762  

Cost of revenue

    1,048                   1,048  

Research and development expenses

    3,402,160       256,886             3,659,046  

Selling, general and administrative expenses, excluding depreciation and amortization (1)

          (550

)

    4,895,328       4,894,778  

Depreciation and amortization (2)

    4,027             47,474       51,501  

(Loss) income from operations (3)

    (2,995,218

)

    27,409       (4,942,802

)

    (7,910,611

)

Other income (4)

                12,045       12,045  

Net (loss) income

    (2,995,218

)

    27,409       (4,930,757

)

    (7,898,566

)

Total assets, net of depreciation and amortization:

                               

United States

  $ 1,000     $ 38,320     $ 5,839,733     $ 5,879,053  

International

    116,782                   116,782  

Capital expenditures

    120,810             8,406       129,216